Helicos BioSciences Corporation

Helicos BioSciences Files Patent Infringement Lawsuit Against Pacific Biosciences

Helicos BioSciences Files Patent Infringement Lawsuit Against Pacific Biosciences

September 8, 2010

CAMBRIDGE, Mass., Sep 08, 2010 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS) announced today that it has filed a lawsuit against Pacific Biosciences of California, Inc. for patent infringement. The lawsuit, filed in the United States District Court for the District of Delaware, accuses PacBio of infringing four patents and seeks injunctive relief and monetary damages.

Acceleron Pharma, Inc.

Acceleron Pharma Announces Joint Development and Commercialization Agreement with Shire on Novel Muscle Therapeutics for Orphan Diseases

Acceleron Pharma Announces Joint Development and Commercialization Agreement with Shire on Novel Muscle Therapeutics for Orphan Diseases

September 9, 2010

$498 Million Deal Grants Shire Exclusive Ex-North American Rights to Acceleron’s Innovative Class of ActRIIB Molecules Including ACE-031, Currently in Phase 2 Trials to Treat Patients with Duchenne Muscular Dystrophy

Joule Unlimited, Inc.

Joule Awarded Patent on Renewable Diesel Production from Sunlight and CO2

Joule Awarded Patent on Renewable Diesel Production from Sunlight and CO2

September 14, 2010

Breakthrough process overcomes the costs and complexities of biomass-to-fuel

TripAdvisor LLC

Kennedy Space Center tops the list of favorite U.S. family summer attractions researched on the Web

Kennedy Space Center tops the list of favorite U.S. family summer attractions researched on the Web

June 24, 2003

TripAdvisor study reveals national parks and aquariums dominate the list of favorite "Things to Do" on family vacations this summer

Morphotek, Inc.

Morphotek announces research collaboration and license agreement with Novo Nordisk for improvements to a protein process of a marketed therapeutic protein

Morphotek announces research collaboration and license agreement with Novo Nordisk for improvements to a protein process of a marketed therapeutic protein

July 7, 2003

Exton, Pa, July 7, 2003 - Morphotek, Inc. today announced that it has entered into a Research Collaboration and License Agreement with Novo Nordisk (NYSE: NVO) for the use of Morphotek's MORPHODOMA™ and DIRECT-LINE® technology to make significant improvements to a protein process of a marketed Novo Nordisk therapeutic protein.

Hypnion, Inc.

Hypnion founders elected to National Academy of Sciences

Hypnion founders elected to National Academy of Sciences

July 8, 2003

Elections represent highest honors accorded U.S. scientists, underscore significance of company's scientific research and developments in chronic sleep-wake disorders

From dBusinessNews.com, July 8, 2003

WORCESTER - Hypnion, Inc., a pioneering neuroscience drug discovery company focused on sleep-wake neurobiology and pharmaceuticals, today announced that two of its founders - Michael Rosbash and Joseph S. Takahashi - have been elected to the National Academy of Sciences (NAS).

Affinnova, Inc.

Design software firm Affinnova sees $6M Series B

Design software firm Affinnova sees $6M Series B

July 9, 2003

By Estee Pierce of VentureWire, July 9, 2003

CAMBRIDGE, Mass. - Affinnova, a developer of software that applies genetic algorithm technologies for use in consumer product design, is expected to announced that it has raised $6 million in a Series B round financing. Lead investor Flagship Ventures provided the full sum of the round, and is the sole outside shareholder in Affinnova. The company was founded in 2000 as an incubator company of NewcoGen Group, which is part of Flagship's family of funds along with OneLiberty, also a past investor in Affinova.

Affinnova, Inc.

Affinnova adds $6 million in B round from Flagship Ventures

Affinnova adds $6 million in B round from Flagship Ventures

July 9, 2003

Cambridge, Mass. - July 9, 2003 - Affinnova, a leading provider of product design, development, and testing solutions, announced today that it has completed a $6 million Series B round of financing led by Flagship Ventures. This latest financing round is expected to accelerate the market penetration of Affinnova's solutions coming on the heels of a six-month period when the Company recorded revenue growth of more than 120% over prior year.

EXACT Sciences

Exact Sciences reaches $15 million milestone

Exact Sciences reaches $15 million milestone

August 13, 2003

Exact Sciences Corp. of Marlborough said it has achieved the $15 million milestone associated with the national commercial availability of PreGen-Plus, which is intended for early detection of colorectal cancer.

This is the second $15 million milestone achieved in connection with the licensing agreement Exact Sciences and Laboratory Corp. of America Holdings entered into in June 2002. PreGen-Plus is Exact Sciences' proprietary DNA-based stool assay for the early detection of colorectal cancer.

Renovis

Renovis raises $45.0 million in private placement

Renovis raises $45.0 million in private placement

August 11, 2003

South San Francisco, California - August 11, 2003 - Renovis, a biopharmaceutical company focused on the discovery and development of drugs to treat neurological diseases and disorders, announced today the completion of its Series E Preferred Stock financing totaling $45.0 million. Easton Hunt Capital Partners led the financing, which included first-time investments from HealthCap, MDS Capital, Invus Group, CDIB BioScience Ventures, and others.